Neurocrine Partners With Takeda to Address Psychiatric Disorders

San Diego – June 29, 2020 – Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company. Cooley lawyers Kay Chandler and Rena Kaminsky led the team advising Neurocrine.

“We are excited to collaborate with Takeda to bring life-changing therapies to people living with serious, challenging and under-addressed psychiatric disorders who are in need of better treatment options,” Neurocrine CEO Kevin Gorman said in a statement. “With our deep understanding in the fields of psychiatry and neurology, we look forward to developing new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline.”

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.

Headquartered in San Diego, Neurocrine specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids and clinical development programs in multiple therapeutic areas. 

Last year, Cooley advised Neurocrine on a collaboration agreement with Xenon and with Voyager.  

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.